Good Morning Market Enthusiast,
Every now and then, a small biotech story starts flashing signals that are hard to ignore.
Not hype.
Not noise.
Actual clinical data. A raised analyst target. A broadened neuroinflammation platform. And a setup that still looks wildly under-followed
compared to the scale of the science.
That is what caught our attention tonight.
The name we are preparing to reveal just reported updated clinical data from an ongoing Expanded Access program in non-active Secondary Progressive Multiple Sclerosis, a difficult area where treatment choices remain limited.
The latest update covered 14 patients and showed:
Clinical trend data pointing toward disability stabilization.
No new safety signals identified.
64% of patients reaching a clinically meaningful fatigue improvement threshold.
Only one confirmed disability progression event in the cohort.
A broader platform already moving across multiple neurodegenerative conditions.
And that is only part of the
setup.
A fresh analyst note just raised its 12-month price target to $9, with the table showing over 566.7% to target from the listed price of $1.35.
Translation?
The street may be starting to wake up to something that has been sitting in plain sight.
This is still early-stage
biotech, so nothing here is risk-free. But when a tiny Nasdaq name has clinical data, a broadened neuro platform, active Phase 2 programs, and a price target implying over 450% potential from current levels, it deserves a closer look.
We are dropping the full breakdown today at 11am ET.
This one has the kind of “wait, how did I
miss that?” setup that can pull attention fast.
Watch your inbox.
To your success,
Max Masters
Co-founder, Market Tips Newsletter
